Royal Philips and New York City-based Memorial Sloan Kettering Cancer Center joined forces to develop genome analytics for pancreatic cancer.
Under the agreement, researchers, data scientists and genomics experts from Philips and Sloan Kettering will apply large-scale DNA sequencing and advanced analytics to pancreatic cancer tumors. Using the Philips IntelliSpace Genomics platform, the collaborators will identify single-cell differences between pancreatic cancer tumors.
The project's goal is to inform personalized cancer treatments based on tumor composition. Philips will share findings from the collaboration through research applications on its platform.
"Collaborating with MSK and its experts will allow us to take a unique approach to diagnosing and treating this devastating disease," said Henk van Houten, chief technology officer at Philips. "We can gain new insights into the origin, development and optimal treatment of pancreatic cancer, and share these insights broadly with care providers to help improve outcomes for patients."